Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194114 | 0.85 | MTNR1A (0.34) | MTNR1AMTNR1BPOLBTDP1PDE10A | |
| SCHEMBL1450761 | 0.75 | CYP1A2 (0.52) | POLBKDM4ECYP1A2 | |
| SCHEMBL194247 | 0.74 | KDM4E (0.58) | KDM4EALDH1A1HPGDNNMTL3MBTL1 | |
| SCHEMBL28617539 | 0.74 | HTT (0.42) | KDM4EALDH1A1HPGDCYP1A2KMT2A | |
| SCHEMBL16751340 | 0.71 | PDE10A (0.46) | MTNR1AMTNR1BPOLBTDP1PDE10A | |
| SCHEMBL621727 | 0.71 | KDM4E (0.53) | POLBKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL29392943 | 0.71 | KDM4E (0.53) | POLBKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL4067343 | 0.71 | NCF1 (0.53) | KDM4EHPGD | |
| SCHEMBL4850106 | 0.70 | MAPK1 (0.40) | KDM4EALDH1A1HPGDCYP1A2KMT2A | |
| SCHEMBL6232953 | 0.69 | CRHBP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
| EP-0035228-B1 | TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4372953-A | Tetrazole derivatives, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0035228-A1 | Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | MTNR1A 2822/4885MTNR1B 1434/4885POLB 1242/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | MTNR1A 3189/4885MTNR1B 2041/4885POLB 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.